KND Labs Receives API Certification for CBD Ingredients
KND Labs earned the Active Pharmaceutical Ingredients (API) accreditation and is now recognized as a certified manufacturer of CBD for pharmaceutical applications.
The manufacturer is one of the only companies in the world with both the API accrediation and certification from the National Animal Supplement Council. Additionally, KND recently submitted its UK Novel Foods ingredient application for review by the European Union.
All KND products include its pure, plant-based CBD ingredients and customizable blends. KND’s formulations adhere to the highest-quality standards for manufacturing and testing to achieve the safest product available on the market. Currently, KND produces 1.2 billion doses per month, with the ability to increase capacity with new partners.
KND underwent a rigorous review of all manufacturing methods and processes by an independent third-party auditor to ensure the products have the highest-quality ingredients possible to provide reliability and consistency for finished goods to be used within pharmaceuticals.
In addition to being API and NASC certified, KND is cGMP 111 and 117 certified, ISO 9001:2015 certified and EFfCI (cosmetic euGMP) certified, as well as Kosher certified.
“We are thrilled to receive our API certification and the ability to propel CBD into the pharmaceutical space,” said Nich Wilson, president of KND. “With the [Drug Enforcement Administration (DEA)]’s recent announcement they have de-scheduled CBD for prescription purposes, this is a historic time for our industry and we are excited to be leading the way.”
KND Labs continues to be fully operational during the COVID-19 pandemic as CBD sales have increased and KND continues to acquire clients in the pharmaceutical and pet industries resulting from new certifications.